Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 2/2016

01-02-2016 | Editorial

Treating Irritable Bowel Syndrome: A Fresh and Minty Approach to an Old Therapy

Author: Lucinda A. Harris

Published in: Digestive Diseases and Sciences | Issue 2/2016

Login to get access

Excerpt

At the hairdresser’s the other day, the beautician applied a conditioner that contained peppermint oil (PO). My scalp felt cooled and soothed, and the scent was very calming. As I contemplated writing this editorial, it occurred to me that even my hairdresser was aware of the wisdom of the ages that PO is used to soothe and calm. In fact, the Internet touts 21 uses for PO, five of which are for digestive issues, with the number one indication being the treatment for irritable bowel syndrome (IBS). …
Literature
1.
Camilleri M. Peripheral mechanisms in irritable bowel syndrome. New Engl J Med. 2012;367:1626–1635.CrossRefPubMed
2.
Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163–173.CrossRefPubMed
3.
Rozza AL, Hiruma-Lima CA, Takahira RK, Padovani CR, Pellizon CH. Effect of menthol in experimentally induced ulcers: pathways of gastroprotection. Chem Biol Interact. 2013;206:272–278.CrossRefPubMed
4.
Rozza AL, Meira de Faria F, Souza Brito AR, Pellizzon CH. The gastroprotective effect of menthol: involvement of anti-apoptotic, antioxidant and anti-inflammatory activities. Plos One. 2014;9:1–6.CrossRef
5.
Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle: an analysis using patch clamp electro-physiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology. 1991;101:55–65.PubMed
6.
Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988;2:101–118.CrossRefPubMed
7.
Walstab J, Wohlfarth C, Hovius R, et al. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders. Neurogastroentorol Motil. 2014;26:810–820.CrossRef
8.
Khanna R, MacDonald J, Levesque B. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48:505–512.PubMed
9.
Ford AC, Moayeddi P, Lacy B, et al. American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109:S2–S26.CrossRefPubMed
10.
Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci (Epub ahead of print). doi:10.​1007/​s10620-015-3858-7.
11.
Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. 2007;39:530–536.CrossRefPubMed
12.
13.
14.
Camilleri M, Lembo AJ, Lavins BJ, et al. Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C. United Eur Gastroenterol J. 2015;3:53–62.CrossRef
15.
16.
Grigleit HG, Grigleit P. Peppermint oil in irritable bowel syndrome. Phytomedicine. 2005;12:601–606.CrossRef
17.
Somerville KW, Richmond CR, Bell GD. Delayed release peppermint oil capsules (Colpermin) for the spastic colon syndrome: a pharmacokinetic study. Br J Clin Pharmacol. 1984;18:638–640.PubMedCentralCrossRefPubMed
18.
19.
Wilson D, Evans M, Weaver E, Shaw AL, Klein GL. Evaluation of a serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2013;6:49–60.PubMedCentralPubMed
20.
Imai H, Osawa K, Yasuda H, Hamashima H, Arai T, Sasatsu M. Inhibition by the essential oils of peppermint and spearmint of the growth of pathogenic bacteria. Microbios. 2001;106:31–39.PubMed
21.
O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551.CrossRefPubMed
Metadata
Title
Treating Irritable Bowel Syndrome: A Fresh and Minty Approach to an Old Therapy
Author
Lucinda A. Harris
Publication date
01-02-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-4004-2

Other articles of this Issue 2/2016

Digestive Diseases and Sciences 2/2016 Go to the issue

Paradigm Shifts in Perspective

The Doppler Effect: A Century from Red Shift to Red Spot

Original Article

Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation

Original Article

The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease

Original Article

Protective Effects of Simvastatin Against Alendronate-Induced Gastric Mucosal Injury in Rats

Stanford Multidisciplinary Seminars

Intractable Diarrhea in Two Brothers: Late Diagnosis of Tufting Enteropathy in Adolescence

Editorial

Bin1 Antibodies for IBD Therapy: Is Permeability the Answer BAR None?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits